Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy
This article was originally published in The Pink Sheet Daily
Abbott will gain Piramal's branded generics unit, expected to generate more than $500 million in sales in 2011.
You may also be interested in...
Pfizer, Novartis and Abbott reportedly are battling to buy out family-owned Ache, Brazil’s leader in prescription drug sales. Plus deals involving AstraZeneca and AlphaCore, Pfizer and Bind Therapeutics and Merck and Ra Pharma.
Abbott licenses 24 drugs from Zydos and forms an Established Products Division focused on emerging markets.
MUMBAI - Indian drug maker Piramal Healthcare's ambition to grow into a world player in hospital and critical care products is set to cross another milestone with the likely acquisition of a few brands in the anesthesia segment from an unlisted Indian pharmaceutical company